Evidence map›Paper›PMID 28831527›Full record

ArticleEuropean journal of clinical pharmacology2017

Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Elisabetta Poluzzi, I Diemberger, M De Ridder, A Koci, M Clo, A Oteri, S Pecchioli, I Bezemer, T Schink, S Pilgaard Ulrichsen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elisabetta PoluzziDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. elisabetta.poluzzi@unibo.it.ORCID http://orcid.org/0000-0002-7209-0426
I DiembergerDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
M De RidderDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
A KociDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
M CloRegione Emilia Romagna Health Authority, Bologna, Italy.
A OteriDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
S PecchioliHealth Search, Italian College of General Practitioners, Florence, Italy.
I BezemerPHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands.
T SchinkLeibniz Institute for Epidemiology and Prevention Research - BIPS, Bremen, Germany.
S Pilgaard UlrichsenDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
G BorianiDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
M C J SturkenboomDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
F De PontiDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
G TrifiròDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAfter regulatory restrictions for terfenadine and astemizole in '90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of individual antihistamines.

methodsA matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project. Data on 1997-2010 were retrieved from seven healthcare databases: AARHUS (Denmark), GEPARD (Germany), HSD and ERD (Italy), PHARMO and IPCI (Netherlands) and THIN (UK). Cases of VA were selected and up to 100 controls were matched to each case. The odds ratio (OR) of current use for individual antihistamines (AHs) was estimated using conditional logistic regression.

resultsFor agents largely used to prevent allergic symptoms, such as cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, we found no VA risk. A statistically significant, increased risk of VA was found only for current use of cyclizine in the pooled analysis (ORadj, 5.3; 3.6-7.6) and in THIN (ORadj, 5.3; 95% CI, 3.7-7.6), for dimetindene in GEPARD (ORadj, 3.9; 1.1-14.7) and for ebastine in GEPARD (ORadj, 3.3; 1.1-10.8) and PHARMO (ORadj, 4.6; 1.3-16.2).

conclusionsThe risk of VA associated with a few specific antihistamines could be ascribable to heterogeneity in pattern of use or in receptor binding profile.

Indexed as

AgedCase-Control StudiesEuropeFemaleHistamine AntagonistsHumansMaleMiddle AgedOdds RatioRiskTachycardia, VentricularHistamine AntagonistsAntihistaminesArrhythmiaCase-control studyDrug safetyHealthcare databases

Identifiers

PMID28831527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.